XML 71 R61.htm IDEA: XBRL DOCUMENT v3.23.1
Note 14 - Litigation Settlement (Details Textual) - USD ($)
 3 Months Ended 12 Months Ended
Jun. 10, 2022
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2022
Sep. 30, 2022
Litigation Settlement, Expense   $ 0   $ 5,191,000    
Biostage [Member] | Series E Convertible Preferred Stock into Common Stock [Member]            
Conversion of Stock, Shares Converted (in shares)   200        
Conversion of Stock, Shares Issued (in shares)   31,933        
Conversion of Stock, Amount Issued   $ 200,000        
Series E Preferred Stock in Biostage [Member]            
Equity Securities without Readily Determinable Fair Value, Amount $ 3,900,000          
Preferred Stock, Book Value, Inclusive of Accrued Dividends   $ 4,000,000.0        
Convertible Preferred Stock [Member] | Biostage [Member]            
Preferred Stock, Dividend Rate, Percentage         8.00%  
Preferred Stock, Par or Stated Value Per Share (in dollars per share)         $ 1,000  
Preferred Stock, Mandatory Conversion, Minimum Qualified Offering Amount         $ 4,000,000  
Case in Suffolk Superior Court [Member]            
Loss Contingency, Estimate of Possible Loss       $ 5,200,000    
Litigation Settlement, Expense     $ (4,900,000)      
Case in Suffolk Superior Court [Member] | Convertible Preferred Stock [Member]            
Estimated Litigation Liability           $ 500,000
Stock Issued During Period, Shares, Issued For Settlement (in shares) 4,000          
Stock Issued During Period, Value, Issued for Settlement $ 4,000,000.0